Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 672

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 672
---
 price includes the amount of fixed consideration the Group expects to receive. Revenue generated is recognized at a point in time when each performance obligation is satisfied. The transaction price is allocated between the two performance obligations by the amount that represents the portion of the consideration to which the entity expects to be entitled in exchange for transferring the services promised to the customer, based on the relative stand -aloneselling price. 2.5Property, plant and equipment, net Property, plant and equipment assets are measured at historical cost less accumulated depreciation and impairment loss, if any. The cost of property, plant and equipment is the fair value of the consideration initially provided to acquire or construct the item and prepare it for use. Subsequent costs incurred for repair and maintenance are expensed in the statements of comprehensive income unless these costs meet the criteria for capitalization (i.e. extension of the useful life). Depreciation commences when the assets are ready for use. Property, plant and equipment is depreciated based on the straight -linemethod over estimated useful lives. An item of property, plant and equipment will be derecognized upon disposal or when future economic benefits from the continued use of the asset are no longer expected. The gain or loss arising from the derecognition is measured as the difference between the gain on sale and the carrying amount of the asset and is recognized through profit or loss. The useful lives of property, plant and equipment are:

| Machinery and equipment |     | 10 years     |
| Furniture and fixtures  |     | 10 years     |
| Computer equipment      |     | 3 – 5 years  |
| Instrumental            |     | 5 – 10 years |

2.6Intangible assets The Group’s development activities involve a plan or design to produce new tests or products for the Heritas Diagnostics segment and development for the Rewell segment. Development costs of new genetic tests within the Heritas Diagnostics segment consist of capitalized internally generated costs that are directly attributable to the development and setup of identifiable genetic tests controlled by the Group. Development costs within the Rewell segment consist of capitalized internally generated costs that are directly attributable to the design, development, and testing of identifiable and unique applications (development related to software) controlled by the Group. These developments are primarily included within the Group’s proprietary GetRewell digital platform.

F-132

Notes to Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 2.Summary of significant accounting policies and basis of preparation (cont.) Development costs are capitalized